Summary
- BioMarin caught a strong bid on the back of its Roctavian label advancing toward FDA approval.
- Investors reward new product developments, and in biotech/pharma, the prospect of new products, research shows.
- Hence, there is scope for those speculating on late-stage clinical assets to harvest a short-term alpha opportunity of 38% with an exit at $162 by estimation.
- The company's business model lacks competitive advantage, evidenced by the numbers, hence it needs the Roctavian approval by estimation.
- Net-net, rate speculative buy.
For further details see:
BioMarin: Tactical Allocation Playing Roctavian Approval